Kineta(KA) - 2023 Q4 - Annual Results

Exhibit 99.1 Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose level in the VISTA-101 trial Cleared fifth of six monotherapy cohorts and second of four combination cohorts in the VISTA-101 trial Kineta is actively exploring strategic alternatives to maximize value for all stakeholders ...